Qualigen Therapeutics Presents Data on QN-302 at AACR’s Pancreatic Cancer Meeting
Posters include data regarding 1) mode of action, and
2) preclinical toxicology
Related news for (QLGN)
- Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K
- Qualigen Therapeutics Announces Regained Compliance with Nasdaq’s Minimum Bid Price Requirement and the Equity Requirement
- Univest Securities, LLC Announces Successful Closing of $5.1 Million Private Placement for Qualigen Therapeutics, Inc. (NASDAQ: QLGN)
- Qualigen Therapeutics Announces $4.5 Million Private Placement of Convertible Preferred Shares
- qualigen therapeutics, inc. announces management changes.